Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Shuttle Pharmaceuticals Inc (SHPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SHPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.54% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.68M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.41 | 52 Weeks Range 3.00 - 107.40 | Updated Date 06/29/2025 |
52 Weeks Range 3.00 - 107.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -69.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -115.05% | Return on Equity (TTM) -346.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34845478 | Price to Sales(TTM) - |
Enterprise Value 34845478 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.67 | Shares Outstanding 10984300 | Shares Floating 411243 |
Shares Outstanding 10984300 | Shares Floating 411243 | ||
Percent Insiders 5.82 | Percent Institutions 0.94 |
Upturn AI SWOT
Shuttle Pharmaceuticals Inc
Company Overview
History and Background
Shuttle Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to improve outcomes for cancer patients undergoing radiation therapy. Founded to address the unmet needs in cancer care, the company is developing drugs designed to sensitize tumors to radiation and protect healthy tissue.
Core Business Areas
- Drug Development: Focused on developing radioprotective and radiosensitizing therapies for cancer treatment. Shuttle Pharmaceuticals has several drug candidates in preclinical and clinical development.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and business management. Organizational structure is typical of a clinical-stage biotech with emphasis on R&D and clinical operations.
Top Products and Market Share
Key Offerings
- Ropidoxuridine: A radiosensitizer in clinical development for glioblastoma. This drug aims to improve the efficacy of radiation therapy in treating brain tumors. Competitors include drugs that are radiosensitizers or other forms of cancer treatment, with companies such as Merck (KEYTRUDA) and Roche (AVASTIN) offering alternate treatment paths. Market share is not currently measurable, as ropidoxuridine is still in clinical development.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in oncology, is highly competitive and regulated, with increasing demand for targeted therapies. The radiation oncology market is growing, driven by advancements in technology and an aging population. Clinical-stage companies require significant capital to prove their drugs safety and efficiency
Positioning
Shuttle Pharmaceuticals is positioned as a developer of novel therapies to improve radiation therapy outcomes. Its competitive advantage lies in its focus on radiosensitizers and radioprotectors.
Total Addressable Market (TAM)
The total addressable market is difficult to determine precisely, but the global radiation oncology market is estimated to be worth billions of dollars annually. Shuttle Pharmaceuticals targets specific cancer types treated with radiation therapy. The total market is vast but not all of it is addressable by Shuttle Pharmaceuticals.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs in radiation oncology
- Experienced management team
- Focus on a specific therapeutic area
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical-stage company with inherent development risks
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results leading to regulatory approval
Threats
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- LLY
Competitive Landscape
Shuttle Pharmaceuticals competes with larger pharmaceutical companies in the oncology space. Its advantage lies in its focus on radiosensitizers, but it faces significant competition from established players with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development activities.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for ropidoxuridine and exploring new therapeutic applications.
Summary
Shuttle Pharmaceuticals is a clinical-stage biotech focusing on innovative cancer therapies and radiosensitization. Its growth trajectory is heavily reliant on successful clinical trials and potential partnerships. The company faces significant competition from major pharmaceutical firms and must navigate regulatory challenges to commercialize its products. While having a novel approach, financial constraints pose a threat, as its products have yet to generate revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on available information and may be subject to change. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Shuttle Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2022-08-31 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.shuttlepharma.com |
Full time employees 9 | Website https://www.shuttlepharma.com | ||
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.